• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents.

作者信息

Tanaka Michi, Sakai Ryoko, Koike Ryuji, Harigai Masayoshi

机构信息

Department of Pharmacovigilance, and Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical Dental University;

Department of Pharmacovigilance, and Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical Dental University, and Clinical Research Center, Tokyo Medical Dental University Hospital;

出版信息

J Rheumatol. 2015 Sep;42(9):1726-8. doi: 10.3899/jrheum.141510.

DOI:10.3899/jrheum.141510
PMID:26330129
Abstract
摘要

相似文献

1
Pneumocystis Jirovecii Pneumonia in Japanese Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Pooled Analysis of 3 Agents.日本类风湿关节炎患者使用肿瘤坏死因子抑制剂治疗后发生耶氏肺孢子菌肺炎：三种药物的汇总分析
J Rheumatol. 2015 Sep;42(9):1726-8. doi: 10.3899/jrheum.141510.
2
Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.类风湿关节炎真实队列中3种抗肿瘤坏死因子生物制剂的直接比较疗效
J Clin Rheumatol. 2016 Mar;22(2):57-62. doi: 10.1097/RHU.0000000000000358.
3
Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.英夫利昔单抗、依那西普和阿达木单抗在类风湿关节炎患者中的真实世界成本效益：CREATE注册研究结果
Rheumatol Int. 2016 Feb;36(2):231-41. doi: 10.1007/s00296-015-3374-2.
4
Pneumocystis jirovecii pneumonia developed in a patient with rheumatoid arthritis after 14 weeks of iguratimod add-on to treatment with methotrexate and etanercept.一名类风湿关节炎患者在甲氨蝶呤和依那西普治疗基础上加用艾拉莫德14周后发生了耶氏肺孢子菌肺炎。
Mod Rheumatol. 2018 Nov;28(6):1041-1043. doi: 10.1080/14397595.2016.1181026. Epub 2016 May 16.
5
[Pneumonia, pneumocystis pneumonia].[肺炎，肺孢子菌肺炎]
Nihon Rinsho. 2007 Jul;65(7):1314-20.
6
Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.阿达木单抗、依那西普和英夫利昔单抗作为类风湿关节炎患者一线生物治疗药物在日常临床实践中的留存率——奥弗涅地区的经验
Int J Rheum Dis. 2018 Nov;21(11):1924-1932. doi: 10.1111/1756-185X.13156. Epub 2017 Sep 13.
7
Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.接受肿瘤坏死因子抑制剂或利妥昔单抗治疗的类风湿关节炎患者中严重感染和恶性肿瘤的发生率。
J Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.
8
Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.类风湿关节炎中肿瘤坏死因子拮抗剂停药比较的异质性——一项荟萃分析
PLoS One. 2016 Dec 8;11(12):e0168005. doi: 10.1371/journal.pone.0168005. eCollection 2016.
9
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.皮下注射英夫利昔单抗与阿达木单抗、依那西普和静脉注射英夫利昔单抗治疗类风湿关节炎患者的疗效和安全性：系统文献回顾和荟萃分析。
Expert Rev Clin Immunol. 2021 Jan;17(1):85-99. doi: 10.1080/1744666X.2020.1858803. Epub 2020 Dec 28.
10
Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.类风湿关节炎患者使用依那西普治疗相关的卡氏肺孢子菌肺炎：15 例回顾性研究及危险因素分析。
Mod Rheumatol. 2012 Nov;22(6):849-58. doi: 10.1007/s10165-012-0615-z. Epub 2012 Feb 22.

引用本文的文献

1
Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.肺孢子菌引起的侵袭性真菌感染的特征和全球影响：一项系统评价，为世界卫生组织真菌优先病原体清单提供信息。
Med Mycol. 2024 Jun 27;62(6). doi: 10.1093/mmy/myae038.
2
Pneumocystosis in a patient with rheumatoid arthritis on adalimumab therapy: a case-based review.阿达木单抗治疗类风湿关节炎患者并发肺囊虫肺炎：基于病例的综述。
Rheumatol Int. 2024 Feb;44(2):363-367. doi: 10.1007/s00296-023-05483-3. Epub 2023 Oct 18.
3
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Janus 激酶抑制剂在类风湿关节炎和其他免疫介导的炎症性疾病中的选择性：期望是一切痛苦的根源吗？
Drugs. 2020 Aug;80(12):1183-1201. doi: 10.1007/s40265-020-01349-1.
4
Comparison of the Clinical Characteristics of Pneumocystis Pneumonia between Patients with Rheumatoid Arthritis Being Treated with Biologics and Those Being Treated without Biologics.接受生物制剂治疗的类风湿关节炎患者与未接受生物制剂治疗的患者间肺孢子菌肺炎临床特征的比较
Biomed Res Int. 2017;2017:3710652. doi: 10.1155/2017/3710652. Epub 2017 Jul 12.
5
Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial.用于系统性风湿性疾病患者预防肺孢子菌肺炎的磺胺甲恶唑-甲氧苄啶最佳方案：一项非盲法随机对照试验的结果
Arthritis Res Ther. 2017 Jan 18;19(1):7. doi: 10.1186/s13075-016-1206-8.